Analysis Of Different Dosages Of Gemcitabine In The Treatment Of Advanced Non-small Cell Lung Cancer

Objective:To evaluate the clinical efficacy and toxicities of advanced non-small cell lung cancer (NSCLC) treated by different dose of gemcitabine combined with cisplatin (GEM+DDP, GP)Method:this study reviewed the100patients with advanced NSCLC treated with different dose of GEM. These100patients were divided into two groups according the dose of GEM:high-dose and low-dose group. The low-dose group include56cases who received gemcitabine1000mg/m2by intravenous infusion on1st and8days and cisplatin75mg/m2by intravenous infusion on1st to3rd in the21-day cycle. The treatment was executed2cycles and then evaluated therapeutic effects and toxicity reaction. The high-dose group include44cases who received gemcitabine1250mg/m2by intravenous infusion on1st and8th days and cisplatin75mg/m2by intravenous infusion on1st to3rd in the21-day cycle. The treatment was executed2cycles and then evaluated therapeutic effects and toxicity reaction. Finally, compared two groups with the objective response rat (ORR) and toxicity.Results:①Therapeutic effects:overall objective response rate (complete response+partial response):the ORR of low-dose and high-dose group were48.2%and45.5%(P>0.05), respectively; disease control rate (CR+PR+SD) of low-dose and high-dose group were75%and81%(P>0.05); The progression-free survival (PFS) of low-dose group was6.9month, compared with7.1month of high-dose group.②Hematological toxicity:grade Ⅲ to Ⅵ myelosupression of low-dose and high-dose group reached10.7%and27.3%(P<0.05=,respectively; Patients in two groups mainly presented grade Ⅰ～Ⅱ non-hematological toxicity, and grade Ⅲ to Ⅳ ausea and vomiting were5.4%and11.4%, respectively;Rash, liver and kidney function harmness, hair loss, and mucositis had no statistical significance.Conclusion:Gemcitabine combined with cisplatin in the first-line treatment of advanced non-small cell lung cancer (ORR) and rate of progression-free survival (PFS) was not significantly different, but III-IV of platelet and white blood cells decreased in1g group was significantly lower than that of1.25g group, has the significance to guide the clinical treatment.(2Picture,6Outside,47Reference)...